HUE026869T2 - Fingolimod adagolási rendje szklerózis multiplex kezelésére - Google Patents

Fingolimod adagolási rendje szklerózis multiplex kezelésére Download PDF

Info

Publication number
HUE026869T2
HUE026869T2 HUE09797234A HUE09797234A HUE026869T2 HU E026869 T2 HUE026869 T2 HU E026869T2 HU E09797234 A HUE09797234 A HU E09797234A HU E09797234 A HUE09797234 A HU E09797234A HU E026869 T2 HUE026869 T2 HU E026869T2
Authority
HU
Hungary
Prior art keywords
treatment
days
compound
agonist
dosage
Prior art date
Application number
HUE09797234A
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Olivier David
Michael Looby
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE026869(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE026869T2 publication Critical patent/HUE026869T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Claims (6)

  1. ! - Az alábbi Ha ábra szerinti képíetü, 2~Í«r!Ífio-:b r2“(4-oktíifensl)ebi]propán-l ,3-diol elnevezésű vegyidet szabad formában vagy egy gyógyászmiag eifogatiMó só vagy érmék fos-zfôtja,
    gto; 1®, jefentéss B5 0¾ X* jetesSÉés® <D, Rj# és fi,b jelentése ©H, s.^tesis,s»ipjiex.ïasBelfiSs^^ való alkalmazásra, ábnl : a kezelés kezded időszakában ** adott vegyfilétet %i 25 mg-ó§ kezdeti ti&amp;ps dózisban, majd ezt követte 0,25 rog-os «apt dózisban adjuk, majd a kezelési a 0,5 mg-os standard napi dózissal foiyfatjtsk.
  2. 2. Az I, igénypont: szerinti vegyüiet az 1, igénypont szerinti kezelésben való sllmlnmaásra, aboi a kezelés Jbsziei$'MôsÂà^:lsos^:«g;Â^t csoportból 'Választott: 4 -12 nap, 5 ™ M nap, msxítoom 10 nap, f ~ íö pap, 9 nap, S nap, f nap, ő pap, ói nap vagy 4 nap, 3t Az í, igénypont szerinti: vágyóiét az I. igénypont szerinti kszzóáste 'vató\#a^^^:sW.«:fee®a^.· kezdett időszakának hossza 7 - 10 nap.
  3. 4. Az k. igénypont szerimi vegyidet az i-3. Igénypontok h&amp;meiyike szerind kezelésben való alkalmazást», kaidiólis mellékhatások vagy szívelégtelenség kockázatának kited betegekben:,
  4. 5. Az I. igénypont szerintii vegyidet az 1 -3, igénypontok bármelyik«?szerinti kezelésben való alkalmazásra, railpizben korláteazttk, csökkentjük vagy megelőzzük az olyan nmetek előfordulását, mint a szédülés,, |imeÍ’(lltSÓg:és::szlváöbogásérzés,
  5. 6. Az i. igénypont szerinti vegyüiet az 1 -5. igénypontok bármelyike szerinti kezelésben való alkalmazásra, almi azeodOaíívegyÜléíei olyan betegeknek adjuk. be, akik az: említed vegySlettel: v&amp;íó issrápiát: megszakították vagy szüneteltették.
  6. 7. Az: I. Igénypont szerinti vegyüiet az 1-6, igénypontok btotelyike szerinti kezelésben való alkalmazásra, ahol a sclerosis multiplex relapszusbn-remísszióba kerüld formája vagy prirpéf popesssly sclerosis multiplex van jelen. g. Az L igénypot« szerimi vegyüfet az f -7» igénypontok bármelyike szerinti kezelésben való alkalmsatok sitoí a vegyüiet 2'amÍRú-2-[2-{4-okíiifenil)etiíi|ptopáo- í 3-dioi szabad formában vagy ennek Mdrokloruf a. % Részlet anteiy az alábbi ilg ábra ^prini k%Ws 2:'atamoy2-p-^mln5ifenil)etiijprnpan-l53-dioi egióvezésS yegyületet szabad formásai vagy egy gyégyávmíikg elfogadott só; formájában, vagy a vegypiet egy f ószittpi; tartalmazó
    aboi R.'«jelentése íi,; RSs jetsbtésa till, XJeigmése Ö, 1¾¾ és?5¾¾jekmèse OH, az. I, íg^^tszer&amp;fci alkalmazásra, abat n gyógpzetegjísié^k as l ,: igéaypímibae: meglktíteört, a betegnek a kezelés kezdteti iiöszakákse bs&amp;daadö dézlsöta tanaimsm. 10. &amp;$:>: igésypom szerinti fei! m I. igmypm széritii fcezeissbeb v<# nÜÉH^ amely tartalmazza még a ^egyOtet 0,5 mg-ös: staasáard sági dtósalí is. It:, A 5. vagy IÖ:.: igénypont ms riad kié az !. Ig&amp;sygtm* skösä alkafemzásra, almi a yggyiliet a d-amlaaO-i:5{4-okiíiténü}ci0)propán· | .3-diói szabad Rámában vagy ennek ibdróklödep,
HUE09797234A 2008-12-22 2009-12-21 Fingolimod adagolási rendje szklerózis multiplex kezelésére HUE026869T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29

Publications (1)

Publication Number Publication Date
HUE026869T2 true HUE026869T2 (hu) 2016-08-29

Family

ID=41667217

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE18179301A HUE048717T4 (hu) 2008-12-22 2009-12-21 Az S1P-receptor agonista adagolási rendje
HUE09797234A HUE026869T2 (hu) 2008-12-22 2009-12-21 Fingolimod adagolási rendje szklerózis multiplex kezelésére
HUE18201062A HUE052048T2 (hu) 2008-12-22 2009-12-21 Az S1P receptor agonista adagolási rendje
HUS2000046C HUS2000046I1 (hu) 2008-12-22 2020-11-19 Az S1P receptor agonista adagolási rendje

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE18179301A HUE048717T4 (hu) 2008-12-22 2009-12-21 Az S1P-receptor agonista adagolási rendje

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE18201062A HUE052048T2 (hu) 2008-12-22 2009-12-21 Az S1P receptor agonista adagolási rendje
HUS2000046C HUS2000046I1 (hu) 2008-12-22 2020-11-19 Az S1P receptor agonista adagolási rendje

Country Status (40)

Country Link
US (11) US20100160259A1 (hu)
EP (7) EP3120844A1 (hu)
JP (6) JP2012513401A (hu)
KR (1) KR101347919B1 (hu)
CN (1) CN102264359A (hu)
AR (1) AR074826A1 (hu)
AU (1) AU2009330176C9 (hu)
BR (1) BRPI0923500A2 (hu)
CA (1) CA2747802C (hu)
CL (2) CL2011001529A1 (hu)
CO (1) CO6390117A2 (hu)
CR (1) CR20110274A (hu)
CU (1) CU20110136A7 (hu)
CY (4) CY1116990T1 (hu)
DK (3) DK2379067T3 (hu)
EA (1) EA201100978A1 (hu)
EC (1) ECSP11011222A (hu)
ES (3) ES2810823T3 (hu)
FR (1) FR20C1060I1 (hu)
HN (1) HN2011001759A (hu)
HR (3) HRP20151190T1 (hu)
HU (4) HUE048717T4 (hu)
IL (3) IL213170A0 (hu)
LT (3) LT3453387T (hu)
MA (1) MA32981B1 (hu)
ME (2) ME03802B (hu)
MX (2) MX2011006623A (hu)
NO (1) NO2020038I1 (hu)
NZ (1) NZ593065A (hu)
PE (1) PE20120337A1 (hu)
PL (3) PL3409274T3 (hu)
PT (3) PT3453387T (hu)
RS (2) RS60666B1 (hu)
SG (1) SG171404A1 (hu)
SI (3) SI3409274T1 (hu)
TN (1) TN2011000272A1 (hu)
TW (1) TW201028143A (hu)
UY (1) UY32352A (hu)
WO (1) WO2010075239A1 (hu)
ZA (2) ZA201103863B (hu)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
SI3409274T1 (sl) 2008-12-22 2020-03-31 Novartis Ag Režim odmerjanja za S1P receptor agonist
CA3129729A1 (en) 2009-09-29 2011-04-07 Novartis Ag Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
CN102917698A (zh) * 2010-05-06 2013-02-06 诺瓦提斯公司 二芳基硫醚衍生物的给药方案
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
WO2012162392A1 (en) * 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
PT2885266T (pt) 2012-08-17 2020-05-29 Actelion Pharmaceuticals Ltd Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo
WO2014138502A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
KR101820330B1 (ko) 2013-10-11 2018-01-19 테이코쿠 팔마 유에스에이, 인코포레이티드 국소 스핑고신-1-포스페이트 수용체 효현제 제형 및 이의 사용 방법
WO2015053879A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
EP4074312A1 (en) * 2014-04-10 2022-10-19 Novartis AG Siponimod immediate release dosage regimen for treating autoimmune diseases
AU2015359346B2 (en) 2014-12-11 2020-05-07 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
EP3242666A1 (en) * 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
WO2021158838A1 (en) 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
CA2421893A1 (en) 2000-08-31 2002-03-07 Merck And Co., Inc. Phosphate derivatives as immunoregulatory agents
KR20120125398A (ko) 2002-05-16 2012-11-14 노파르티스 아게 암에서 ｅｄｇ 수용체 결합제의 용도
EP1663188B1 (en) * 2003-09-12 2016-08-10 Newron Sweden AB Treatment of disorders of the nervous system
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP2008521827A (ja) * 2004-11-29 2008-06-26 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストの投与レジメン
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
JP2008537493A (ja) * 2005-02-10 2008-09-18 ジー．アイ． ビュー リミティド ガイド要素を有する胃腸用器具の進行技術
WO2009048993A2 (en) 2007-10-12 2009-04-16 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
WO2009115954A1 (en) * 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
CN104800196A (zh) * 2008-06-20 2015-07-29 诺华股份有限公司 用于治疗多发性硬化的儿科组合物
PL2379069T3 (pl) 2008-12-22 2015-08-31 Novartis Ag Schemat dawkowania agonisty receptora S1P
SI3409274T1 (sl) 2008-12-22 2020-03-31 Novartis Ag Režim odmerjanja za S1P receptor agonist

Also Published As

Publication number Publication date
HUE048717T4 (hu) 2022-02-28
CY2020036I2 (el) 2021-06-25
AU2009330176B2 (en) 2014-03-06
EP2907511A1 (en) 2015-08-19
HRP20201167T1 (hr) 2020-12-11
HUS2000046I1 (hu) 2020-12-28
LT3453387T (lt) 2020-08-25
JP2014144970A (ja) 2014-08-14
EP2379067A1 (en) 2011-10-26
ES2810823T3 (es) 2021-03-09
MA32981B1 (fr) 2012-01-02
MX2011006623A (es) 2011-07-12
HUE052048T2 (hu) 2021-04-28
RS60666B1 (sr) 2020-09-30
IL274756A (en) 2020-07-30
US20140148415A1 (en) 2014-05-29
KR101347919B1 (ko) 2014-01-07
PL3453387T3 (pl) 2020-11-02
CO6390117A2 (es) 2012-02-29
LTPA2020005I1 (lt) 2020-12-10
PT2379067E (pt) 2015-12-23
KR20110096175A (ko) 2011-08-29
HN2011001759A (es) 2013-11-26
SG171404A1 (en) 2011-07-28
EP3453387B1 (en) 2020-06-03
CL2013001558A1 (es) 2013-10-25
SI3409274T1 (sl) 2020-03-31
AU2009330176C9 (en) 2017-01-05
EP3453387A1 (en) 2019-03-13
US20100160259A1 (en) 2010-06-24
HRP20151190T1 (hr) 2016-01-01
US20110257133A1 (en) 2011-10-20
EP4098256A1 (en) 2022-12-07
CA2747802A1 (en) 2010-07-01
NO2020038I1 (no) 2020-11-18
JP2016135752A (ja) 2016-07-28
ES2760607T3 (es) 2020-05-14
JP7329965B2 (ja) 2023-08-21
JP2022103194A (ja) 2022-07-07
CY1123255T1 (el) 2021-10-29
ME03802B (me) 2021-04-20
US20160263061A1 (en) 2016-09-15
PL3409274T3 (pl) 2020-06-01
US20200330407A1 (en) 2020-10-22
PT3409274T (pt) 2019-12-17
WO2010075239A1 (en) 2010-07-01
US20160081949A1 (en) 2016-03-24
CY2020036I1 (el) 2021-03-12
EP3677260A1 (en) 2020-07-08
PT3453387T (pt) 2020-08-11
NZ593065A (en) 2012-11-30
JP2019167360A (ja) 2019-10-03
US20170189353A1 (en) 2017-07-06
DK3453387T3 (da) 2020-08-10
DK2379067T3 (en) 2015-12-07
DK3409274T3 (da) 2019-12-16
AR074826A1 (es) 2011-02-16
PE20120337A1 (es) 2012-04-24
CA2747802C (en) 2021-02-09
UY32352A (es) 2010-07-30
EP3409274A1 (en) 2018-12-05
TN2011000272A1 (en) 2012-12-17
EP2379067B1 (en) 2015-09-02
EP3120844A1 (en) 2017-01-25
US20180289638A1 (en) 2018-10-11
BRPI0923500A2 (pt) 2018-05-29
IL278914A (en) 2021-01-31
IL213170A0 (en) 2011-07-31
CY1122812T1 (el) 2021-05-05
CU20110136A7 (es) 2012-01-31
SI2379067T1 (sl) 2016-01-29
ME03594B (me) 2020-07-20
TW201028143A (en) 2010-08-01
HUE048717T2 (hu) 2020-08-28
CL2011001529A1 (es) 2012-02-24
RS59857B1 (sr) 2020-02-28
LT3409274T (lt) 2020-02-10
US20220142949A1 (en) 2022-05-12
JP2012513401A (ja) 2012-06-14
ZA201103863B (en) 2012-10-31
EP3409274B1 (en) 2019-11-20
EA201100978A1 (ru) 2012-01-30
AU2009330176A1 (en) 2011-07-07
JP2017141238A (ja) 2017-08-17
ES2552823T3 (es) 2015-12-02
PL2379067T3 (pl) 2016-02-29
CR20110274A (es) 2011-07-19
ECSP11011222A (es) 2011-08-31
US20190091180A1 (en) 2019-03-28
AU2009330176C1 (en) 2016-12-08
SI3453387T1 (sl) 2020-10-30
CY1116990T1 (el) 2017-04-05
MX2021010759A (es) 2022-07-19
US20140066657A1 (en) 2014-03-06
CN102264359A (zh) 2011-11-30
FR20C1060I1 (fr) 2020-12-25
HRP20192175T1 (hr) 2020-03-20
ZA201205942B (en) 2013-03-27

Similar Documents

Publication Publication Date Title
DK2379067T3 (en) Dosing regimen to fingolimod FOR THE TREATMENT OF MULTIPLE SCLEROSIS
HUE026400T2 (hu) S1P receptor agonista adagolási rendje
WO2013055833A1 (en) Dosage regimen for a sip receptor agonist
AU2019208233B2 (en) Dosage regimen for a S1P receptor agonist
AU2013204103A1 (en) Dosage regimen for a S1P receptor agonist